Men ages 55 to 69 who are considering prostate cancer screening should talk with their doctors about the benefits and harms of testing and proceed based on their personal values and preferences, according to a new clinical practice guideline released May 3 by the American Urological Association. The guideline states:
--PSA screening in men under age 40 years is not recommended.
--Routine screening in men between ages 40 to 54 years at average risk is not recommended.
--For men ages 55 to 69 years, the decision to undergo PSA screening involves weighing the benefits of preventing prostate cancer mortality in one man for every 1,000 men screened over a decade against the known potential harms associated with screening and treatment. For this reason, shared decision-making is recommended for men age 55 to 69 years that are considering PSA screening, and proceeding based on patients’ values and preferences.
--To reduce the harms of screening, a routine screening interval of two years or more may be preferred over annual screening in those men who have participated in shared decision-making and decided on screening. As compared to annual screening, it is expected that screening intervals of two years preserve the majority of the benefits and reduce over diagnosis and false positives.
--Routine PSA screening is not recommended in men over age 70 or any man with less than a 10-15 year life expectancy.
The new guideline updates the association’s 2009 Best Practice Statement on Prostate-Specific Antigen and brings it more in line with other recommendations, one last year from the U.S. Preventive Services Task Force and another last month by the American College of Physicians.
The guideline does not address detection of prostate cancer in symptomatic men, where symptoms imply those that could be related to locally advanced or metastatic prostate cancer.
The new guideline not only updates the recommendations themselves, but its methodology is based on a systematic literature review rather than consensus opinion; provides rating and interpretation of the evidence based on randomized controlled trials with modeled and population data as supporting evidence; and develops statements that do not go beyond the available evidence. The study's lead author said in a press release that randomized controlled trials are more mature at this point and there is more data available today than there was in 2009.
The highest quality evidence for screening benefit (lower prostate cancer mortality) was in men ages 55 to 69 years screened at two- to four-year intervals; data demonstrated that one man per 1,000 screened will avert a prostate cancer death over a decade. However, over a lifetime, this benefit could be much greater. Furthermore, there are men outside this target age range (55-69 years) that could benefit from screening because they are at a higher risk of prostate cancer (race, family history, etc.). These men should discuss their risk with their physicians and assess the benefits and risks of testing.